文献速递肾小球疾病遗传性与小管间质肾病

慢性汞中毒继发中毒性肾病:临床特征与结局

Toxic Nephropathy Secondary to Chronic Mercury Poisoning: Clinical Characteristics and Outcomes.
PubMed 文献 · Kidney Int Rep · 2022-03-18

该研究回顾性分析了2013年7月至2019年6月6年间诊断为汞中毒的172例患者,其中46例(26.74%)存在肾损害,41例(89.13%)表现为肾病综合征,病理以膜性肾病为主(18/35,51.43%),总体有效率为97.5%(40例),三种治疗方案完全缓解率无显著差异(P < 0.05)。

要点

  • 慢性汞中毒继发肾损害主要表现为肾病综合征,病理以膜性肾病为主。
  • 汞中毒性肾病易误诊漏诊,驱汞治疗是主要治疗手段,预后良好。
  • 病情严重者可辅以糖皮质激素治疗。

核心结论

  • 慢性汞中毒继发肾病的主要临床表现为肾病综合征,病理检查反映为膜性肾病。
  • 慢性汞中毒所致肾病易误诊和漏诊,驱汞治疗是主要治疗方法,预后良好。
  • 病情严重者可辅以糖皮质激素治疗。

研究设计与样本

  • 回顾性分析2013年7月至2019年6月6年间诊断为汞中毒的患者,比较有无肾病患者的人口学、临床指标、肾脏病理检查、治疗和结局。

主要发现

  • 172例汞中毒患者中46例(26.74%)存在肾损害。
  • 46例肾损害患者中41例(89.13%)表现为肾病综合征,5例(10.87%)仅表现为蛋白尿。
  • 汞中毒所致肾病的病理异常主要为膜性肾病(35例中18例,51.43%)。
  • 41例肾病综合征患者中,25例仅接受驱汞治疗,12例接受驱汞联合糖皮质激素治疗,其余4例接受驱汞、糖皮质激素和免疫抑制治疗。
  • 总体有效率为97.5%(40例),三种治疗方法的完全缓解率无显著差异(P < 0.05)。

临床怎么用

  • 驱汞治疗是慢性汞中毒性肾病的主要治疗,预后良好。
  • 病情严重者可辅以糖皮质激素治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Kidney disease secondary to mercury poisoning has not been well documented and is often misdiagnosed and mistreated. METHODS: We performed a retrospective analysis of patients diagnosed with having mercury poisoning over a 6-year period between July 2013 and June 2019. Demographics, clinical measures, renal pathologic examinations, treatments, and outcomes were compared between patients with kidney disease and those without kidney disease. RESULTS: Of the 172 patients with mercury poisoning, 46 (26.74%) had renal damage. Among the 46 patients, 41 (89.13%) presented nephrotic syndrome, and 5 (10.87%) showed proteinuria alone. The pathologic abnormality associated with kidney disease caused by mercury poisoning was mainly membranous nephropathy (18 of 35 patients, 51.43%). Among 41 patients with nephrotic syndrome, 25 were treated with chelation therapy alone and 12 with mercury chelation therapy and glucocorticoids. The remaining 4 patients were treated with chelation therapy, glucocorticoids, and immunosuppressive therapies. The overall effective rate was 97.5% (40 patients). There was no significant difference in complete remission rate among the 3 treatment methods (P < 0.05). CONCLUSION: The main clinical manifestation of kidney disease secondary to chronic mercury poisoning was nephrotic syndrome, which was reflected in pathologic examinations as membranous nephropathy. Kidney disease to chronic mercury poisoning is prone to misdiagnosis and missed diagnosis. Chelation therapy is the main treatment, and the prognosis is good. Patients with severe condition can be supplemented with glucocorticoid.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gao Z, Wu N, Du X, et al. Toxic Nephropathy Secondary to Chronic Mercury Poisoning: Clinical Characteristics and Outcomes. Kidney Int Rep. 2022. PMID: 35694560. doi:10.1016/j.ekir.2022.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。